Earnings
Tectonic Therapeutic Expects Heart-Failure Trial Results By End Of January, With $234.7 Million In Cash
The biotech reported a $21.3 million third-quarter net loss and says its cash should last into the first quarter of 2029.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
The biotech reported a $21.3 million third-quarter net loss and says its cash should last into the first quarter of 2029.
SEC Filings
The company says cash plus expected product revenue should last into the first half of 2028, as it lays out 2026-2027 trial milestones.
SEC Filings
Stockholders re-elected all five directors, backed the pay vote and ratified Baker Tilly US as auditor at the Tuesday annual meeting.
Deals
Pacira will issue no third-quarter results and no outlook updates while Viatris' $36.50-a-share cash tender offer is pending.
Earnings
Third-quarter sales rose 16.7% to $2.56 billion, while aluminum, freight and marketing costs outpaced revenue growth.
SEC Filings
Haynesworth, who chaired the Security Committee until 2026, is not standing for reelection; the board nominated its eight other directors.
SEC Filings
The mall owner's valuation of the Taubman Realty Group purchase is final, and a $25.2 million amortization cut offsets part of the charge.
Earnings
The animal-health company raised its full-year revenue, EBITDA and EPS targets and hit its 2.9x net leverage goal sooner than it expected.
Earnings
The Ukrainian mobile operator posted third-quarter net profit of USD 99 million, against a USD 89 million loss a year earlier.
Earnings
The alternative asset manager's fee-bearing capital reached $682 billion, and its flagship infrastructure fund is nearing a first close.
SEC Filings
The company says it cannot yet estimate how large the corrections to prior-period statements will be, and its review of further errors continues.
Earnings
Third-quarter revenue rose 10% to $30.6 million as gross margin widened to 62%, while the FDA found Hyalofast not approvable.